Table 6 Sensitivity analyses of provider costs
From: Economic evaluation of task-shifting approaches to the dispensing of anti-retroviral therapy
Scenario | Models | Assumptions | Outcomes | Â | |
|---|---|---|---|---|---|
Staff mix | Number of patient visits per year | Average provider cost/ visit | Annual provider cost per patient | ||
Baseline | Full-time pharmacist | Â | Based on exit interview | US$6.55 | US$50.95 |
| Â | ISPA | Â | US$5.74 | US$61.63 | |
| Â | Nurse-driven | Â | US$10.16 | US$99.38 | |
1 | Full-time pharmacist | One pharmacist and one pharmacists assistant | 6 | US$4.61 | US$27.64 |
| Â | ISPA | One supervisory pharmacist and one pharmacists assistant | US$4.46 | US$26.77 | |
| Â | Nurse-driven | One supervisory pharmacist and one nurse | US$11.11 | US$66.65 | |
2 | Full-time pharmacist | One pharmacist, one pharmacist’s assistant and maximum nurse time estimate | 12 | US$8.81 | US$105.72 |
|  | ISPA | Supervisory pharmacist, pharmacist’s assistants and maximum nurse time estimate | US$8.92 | US$107.08 | |
|  | Nurse-driven | Supervisory pharmacist, pharmacist’s assistants and maximum nurse time estimate | US$18.80 | US$225.62 | |